JKJitsu Kato

Jitsu Kato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jitsu Kato has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-Nucleotide Polymorphisms of the PAR2 and IL-17A Genes Are Significantly Associated with Chronic Pain

    by Moe Soeda, Seii Ohka, Daisuke Nishizawa, Masako Iseki, Keisuke Yamaguchi, Hideko Arita, Kazuo Hanaoka, Jitsu Kato, Setsuro Ogawa, Ayako Hiranuma, et al.

    Patients with chronic pain are affected psychologically and socially. There are also individual differences in treatment efficacy. Insufficient research has been conducted on genetic polymorphisms that are related to individual differences in the susceptibility to chronic pain. Autoimmune disorders can lead to inflammation and chronic pain; therefore, we focused on the autoimmune-related protease-activated receptor 2 (PAR2/F2RL1) and interleukin 17A (IL-17A/IL17A) genes. PAR2 and IL-17A are associated with autoimmune diseases that lead to chronic pain, and PAR2 regulates T-helper (Th) cell activation and differentiation. We hypothesized that the PAR2 and IL-17A genes are associated with chronic pain. The present study used a case–control design to statistically examine associations between genetic polymorphisms and the vulnerability to chronic pain. The rs2243057 polymorphism of the PAR2 gene and rs3819025 polymorphism of the IL-17A gene were previously reported to be associated with pain- or autoimmune-related phenotypes. Thus, these polymorphisms were investigated in the present study. We found that both rs2243057 and rs3819025 were significantly associated with a susceptibility to chronic pain. The present findings revealed autoimmune-related genetic factors that are involved in individual differences in chronic pain, further aiding understanding of the pathomechanism that underlies chronic pain and possibly contributing to future personalized medicine.


  • Open Access

    Rs11726196 Single-Nucleotide Polymorphism of the Transient Receptor Potential Canonical 3 (TRPC3) Gene Is Associated with Chronic Pain

    by Yoshinori Aoki, Daisuke Nishizawa, Seii Ohka, Shinya Kasai, Hideko Arita, Kazuo Hanaoka, Choku Yajima, Masako Iseki, Jitsu Kato, Setsuro Ogawa, et al.

    Chronic pain is reportedly associated with the transient receptor potential canonical 3 (TRPC3) gene. The present study examined the genetic associations between the single-nucleotide polymorphisms (SNPs) of the TRPC3 gene and chronic pain. The genomic samples from 194 patients underwent linkage disequilibrium (LD) analyses of 29 SNPs within and around the vicinity of the TRPC3 gene. We examined the associations between the SNPs and the susceptibility to chronic pain by comparing the genotype distribution of 194 patients with 282 control subjects. All SNP genotype data were extracted from our previous whole-genome genotyping results. Twenty-nine SNPs were extracted, and a total of four LD blocks with 15 tag SNPs were observed within and around the TRPC3 gene. We further analyzed the associations between these tag SNPs and chronic pain. The rs11726196 SNP genotype distribution of patients was significantly different from the control subjects even after multiple-testing correction with the number of SNPs. The TT + TG genotype of rs11726196 is often carried by chronic pain patients, suggesting a causal role for the T allele. These results contribute to our understanding of the genetic risk factors for chronic pain.


    • 1 July 2014
      • Vol. 63  (7) , 743-51

    [Device for quantitative analysis of perception and pain sensation].

    by Hideko Arita, Jitsu Kato, Setsuro Ogawa, Kazuo Hanaoka

    The article describes an analysing device that measures the perception and intensity of pain quantitatively. While it is not necessarily true that psychological aspect is totally irrelevant to pain measurement, this device is remarkable in that it is capable of measuring the intensity of pain felt by the patient more objectively by using electric stimuli. The feature of this device is that it uses a non-pain heteresthesia for measuring the intensity of pain. The device is compact, light-weight, and portable. Unlike VAS that requires only a scale, the device requires a person to carry out the measurement. Nevertheless, as the National Health Insurance (NHI) coverage has been approved, introduction of the device may be facilitated in terms of budget for the purchase and labor. The device is useful to better understand not only the intensity of pain but also the pathological conditions, resulting in more appropriate treatment, by (1) comparing degree of pain or VAS values taken by a multicenter study with those of a patient; (2) using both degree of pain and VAS; and (3) multiple measurements of degree of pain and VAS in one case.

  • Open Access

    Incidence and Prognosis of Persistent Pain Induced by Venipuncture for Blood Sampling: An Observational Study over a 5-Year Period

    by Jitsu Kato, Hideo Araki, Masahiro Kimura, Katsuyuki Takahashi, Kaname Ueda, Ryoji Iida, Tomohiro Nakayama, Setsuro Ogawa


  • A portable ultrasound transducer stabilization device for ultrasound-guided nerve blocks

    by Jitsu Kato, Dai Gokan, Miho Shimizu, Ryoji Iida, Setsuro Ogawa

    • 1 October 2011
      • Vol. 60  (10) , 1135-43

    [Effects of the induction of anesthesia with propofol on hemodynamics in patients with Parkinson's disease].

    by Ryo Nakajima, Jitsu Kato, Ken-Ichi Iwasaki, Yojiro Ogawa, Dai Gokan, Setsuro Ogawa

    Patients with Parkinson's disease frequently suffer from impaired autonomic nervous function. To elucidate the effects of the induction of anesthesia with propofol on cardiovascular hemodynamics has become important, since the number of patients with Parkinson's disease undergoing deep brain stimulation under general anesthesia has increased recently. Effects of induction with propofol in patients with Parkinson's disease on cardiovascular hemodynamics and autonomic nervous activity were compared with those of the control patients. Moreover, possible different effect on hemodynamics between the propofol alone and the combination of propofol and fentanyl for the induction were examined in patients with Parkinson's disease. Although heart rate or blood pressure was not different between patients with Parkinson's disease and the control patients before the induction, sympathetic vasomotor activity was lower in patients with Parkinson's disease than the control patients. The induction of anesthesia significantly decreased blood pressure in patients with Parkinson's disease. However the decreasing systolic blood pressure after the induction of anesthesia was more marked in patients with Parkinson's disease than the control patients. We did not find differences in the changes of blood pressure between the propofol alone and the combination of propofol and fentanyl in patients with Parkinson's disease. No abnormal responses to the induction of anesthesia with propofol were found in the patients with Parkinson's disease.

    • 1 January 2011
      • Vol. 60  (1) , 67-74

    [Comprehensive evaluation of the effect of triazolam on amnesia during the preoperative period].

    by Ryoji Iida, Keizo Kajiwara, Akihiro Kashiwai, Jitsu Kato, Setsuro Ogawa

    Triazolam reportedly has greater amnesic potential than other benzodiazepines. The present study was designed to investigate whether this amnesic potential can be applied to surgical patients as premedication, thus relieving them from postoperatively remembering preoperative fears of anesthesia and surgery. We prospectively evaluated the effect on amnesia of triazolam administered during the preoperative period in 80 patients between 20-64 years of age (mean, 43.1 +/- 14.3 years) who underwent surgeries for non-malignant diseases under general anesthesia maintained with sevoflurane and nitrous oxide in oxygen throughout the operation, or general anesthesia maintained with the same anesthetics combined with epidural or spinal anesthesia. Patients with diseases or factors influencing the effect of triazolam, such as a history of mental diseases, recent sedative or antihistamine usage, or current sleep disturbances, were excluded from this study. Triazolam was administered to the 80 patients orally at a dose of 0.375 mg 60 minutes prior to entering the operating room. During structured interviews on postoperative day 1, the patients were asked to state what they remembered of the preoperative period. Amnesia was classified based on the patients' last memory before the anesthetic induction as follows: loss of memory from immediately after taking triazolam, loss of memory at departure from the ward, loss of memory at the entrance to the operating room, loss of memory at the operating table and some recall of events at the operating table. Interviews revealed that 26.3% of the patients experienced loss of memory immediately after taking triazolam, this number increasing to 28.8% of the patients at departure from the ward, 35.0% at the entrance to the operating room and 67.5% on the operating table. The remaining patients (32.5%) had some memory of the operating room and table. Triazolam caused no respiratory depression at the operating table, although 2 of the patients experienced dizziness, 1 patient had nausea and 1 patient felt heavy-headed during the period between taking triazolam and the induction of anesthesia. Although 13 patients had delayed emergence from general anesthesia, these patients remaining anesthetized even 5 minutes after the concentration of sevoflurane in the expired gas decreased and remained below 0.1 percent, all these patients emerged immediately after intravenous administration of flumazenil. The use of triazolam as premedication produced a high incidence of amnesia for preoperative events without causing respiratory depression. Triazolam appears to be a useful premedicant for surgical patients who wish to have no memory at the operating room.


  • Open Access

    Successful Pain Management of Primary and Independent Spread Sites in a Child with CRPS Type I Using Regional Nerve Blocks

    by Jitsu Kato, Dai Gokan, Kaname Ueda, Miho Shimizu, Takahiro Suzuki, Setsuro Ogawa


    • 1 November 2009
      • Vol. 58  (11) , 1360-6

    [Device for measuring salivary alpha-amylase--application for pain assessment].

    by Noriya Hirose, Jitsu Kato

    The salivary enzyme alpha-amylase is an established non-invasive marker of psychological and physiological stress. Since there are positive correlations between salivary alpha-amylase secretion and sympathetic parameter increment during stress, salivary alpha-amylase might be an indicator of sympathetic-adrenal-medullary (SAM) system and central sympathetic activity In contrast, it is well known that sympathetic neural activity is significantly involved in development and deterioration of pain symptoms as a part of pain disorders. Additionally, it has been suggested that various painful stimuli activate SAM system. Taking these data together, salivary alpha-amylase might be an indirect indicator of pain-induced central sympathetic tone. Furthermore, a hand-held device, which is able to measure the activity of salivary alpha-amylase easily and quickly, was developed recently, and we can try to evaluate the condition of pain at the outpatient clinic and the bedside. Though the actual utility of this measuring device for clinical use is unclear, it is hoped that the measuring device of salivary alpha-amylase is one of helpful methods for pain assessment in the future.